Katy Kaufman and her biology and physical science teacher Pam Vaughan from the town of Fordyce High School in Arkansas will set up a tent with displays about comets at the annual Fordyce on the Cottonbelt Festival.
The Cornell Board of Trustees will meet in Ithaca Thursday, May 23, through Saturday, May 25. The Executive Committee of the board will hold a brief open session at the start of its meeting at 9 a.m. Friday, May 24, in the Yale-Princeton Room.
After more than 5,000 years of human-feline cohabitation and enough elaborations on "meow!" to fill a dictionary, cats still haven't mastered language. But a Cornell University evolutionary psychology study - analyzing people's reactions to feline vocalizations - shows that cats know how to get what they want. (May 20, 2002)
New York, NY (May 19, 2002) A physician from Weill Cornell Medical College reported to a meeting of the American Society of Clinical Oncologists (ASCO) in Orlando, FL, today that, in 13 of 16 patients with non-Hodgkin's lymphoma who were treated with an experimental monoclonal antibody called Bexxar, it was still possible to collect an adequate supply of blood stem cells for potential use in a transplant in case the patient relapsed.Dr. Tsiporah Shore, Associate Director of the Bone Marrow and Stem Cell Transplant Program at Weill Cornell, explained that Bexxar (I131 tositumomab) is being tested as a treatment for non-Hodgkin's lymphoma. Bexxar is a monoclonal antibodyan antibody specifically targeted against the antigens of that disease. However, because Bexxar is linked to a radioactive molecule, there has been a concern that exposure to Bexxar "might damage the body's supply of stem cells, which could be needed for a transplant if the patient relapsed," according to Dr. Shore.
New York, NY (May 19, 2002) A physician in Weill Cornell Medical College's Division of Hematology/Oncology is reporting that a recently developed monoclonal antibody, called J591, targets an antigen expressed in the blood vessels of solid tumors. The physician, Dr. Matthew I. Milowsky, who is just finishing a term as a fellow in the division, makes his presentation today to the American Society of Clinical Oncologists (ASCO), which is meeting in Orlando, FL.Dr. Milowsky, who will become an Assistant Professor in the division this July, explains that J591 was developed by a colleague, Dr. Neil Bander, and manufactured by Millennium Pharmaceuticals, of Cambridge, MA. "J591 recognizes the extracellular domain of prostate-specific membrane antigen (PSMA)," Dr. Milowsky says. PSMA, so named because it was first found in the prostate, is present in the blood vessels of numerous solid tumors, but not in normal blood vessels of benign tissues. The hope is that by attaching a radioactive molecule or other anti-cancer agent to J591, doctors will be able to target tumors specifically for the delivery of therapy.
Rob Ryan, a Cornell University alumnus and founder of Ascend Communications Inc. and Entrepreneur America, will be honored by the university Sept. 26 and 27 as the 2002 Cornell Entrepreneur of the Year. Ryan earned national attention when he grew Ascend to more than $500 million in sales between 1989 and 1995. The company is a leading manufacturer of Point of Presence boxes (POP) for Internet providers. A POP is an online service provider's access point to the web, and it usually includes routers, call aggregators, servers and, frequently, relays or switches. Lucent Technologies acquired Ascend in 1999 for $23 billion in one of the nation's largest technology mergers. (May 20, 2002)
New York, NY (May 20, 2002) Investigators from Weill Medical College of Cornell University today reported encouraging interim results with a new potential therapy for non-Hodgkinâs lymphoma (NHL), which affects about 53,900 new patients each year in the United States. The presentation was made at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, FL.Dr. John P. Leonard, the lead investigator of a trial involving a collaboration of scientists from Weill Cornell, Amgen (of Thousand Oaks, CA), and Immunomedics (of Morris Plains, NJ), reported data from 21 patients who have relapsed and refractory NHLpatients in whom the disease has progressed despite prior treatment. The study is the first trial of a combination of two monoclonal antibodies in lymphomaone of the antibodies a known agent (rituximab) and the other a new one (epratuzumab). Administered together, once weekly for four weeks, the combination has preliminarily shown enhanced efficacy over that which has been previously reported with rituximab alone. Rituximab acts against the CD20 antigen (or target molecule) on NHL cells. Its brand name is Rituxan¨, and it is produced by IDEC, of San Diego, Calif., and Genentech, of San Francisco. Epratuzumab, a new investigational antibody in development by Amgen and Immunomedics, acts against the CD22 antigen of NHL.
Cornell University will honor 35 secondary school teachers from as near as Horseheads, N.Y., and from as far away as Singapore, May 21 and 22. The teachers were selected by Cornell's Merrill Presidential Scholars, students who represent the top 1 percent of the university's graduating seniors.
Can not-for-profit universities with boards of trustees learn from corporate boards of directors? Are universities essentially unmanageable places, or are there workable strategies for running them well? And should a university fight or welcome a unionized faculty and staff? These and other pressing issues in higher education will be discussed during "Governance of Higher Education Institutions and Systems," the Cornell Higher Education Research Institute (CHERI) annual conference on Cornell University's campus June 4 and 5. (May 16, 2002)
Technology Review, a magazine published by the Massachusetts Institute of Technology, has named Kelvin H. Lee, assistant professor in the School of Chemical and Biomolecular Engineering at Cornell, among the "World's Top 100 Young Innovators in Technology and Business".
ITHACA, N.Y. --The Cornell University administration was informed May 14, 2002, that a group of graduate students, called the Cornell Association of Student Employees/United Auto Workers (CASE/UAW), has filed a petition with the National Labor Relations Board (NLRB) seeking to be recognized as a collective bargaining agent on behalf of Cornell graduate research assistants, teaching assistants, research assistants, graduate assistants, readers, graders, tutors and consultants. The Cornell administration views this action with serious concern. On the one hand, the university has a long history of participation in both the American and international labor movements. On our own campus, the administration presently bargains with six different bargaining units. These negotiations have always been conducted in good faith by both the university and its represented workers. (May 15, 2002)
